Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.

Cost-effectiveness of GLP-1 receptor agonists versus insulin for the treatment of type 2 diabetes: a real-world study and systematic review

Open access
Yang, Chen-Yi, Chen, Ying-Ren, Ou, Huang-Tz, Kuo, Shihchen · 2021 · Cardiovascular Diabetology

Abstract

Background: To conduct a real-word-study-based cost-effectiveness analysis of a GLP-1 receptor agonist (GLP-1RA) versus insulin among type 2 diabetes patients requiring intensified injection therapy and a systematic review of cost-effectiveness studies of GLP-1RAs versus insulin. Methods: Individual-level analyses incorporating real-world effectiveness and cost data were conducted for a cohort of 1022 propensity-score-matched pairs of GLP-1RA and insulin users from Taiwan’s National Health Insurance Research Database, 2007–2016. Study outcomes included the number needed to treat (NNT) to prevent one case of clinical events, healthcare costs, and cost per case of event prevented. Costs were in 2019 US dollars. Analyses were performed from a third-party payer and healthcare sector perspectives. Structured systematic review procedures were conducted to synthesize updated evidence on the cost-effectiveness of GLP-1RAs versus insulin. Results: Over a mean follow-up of 2.3 years, the NNT using a GLP-1RA versus insulin to prevent one case of all-cause mortality and hospitalized hypoglycemia was 57 and 30, respectively. Using GLP-1RAs instead of insulin cost US$54,851 and US$29,115 per case of all-cause mortality and hospitalized hypoglycemia prevented, respectively, from the payer perspective, and saved US$19,391 and US$10,293, respectively, from the healthcare sector perspective. Sensitivity analyses showed that the probability of using GLP-1RAs versus insulin being cost-effective for preventing one case of all-cause mortality or hospitalized hypoglycemia ranged from 60 to 100%. The systematic review revealed a cost-effective profile of using GLP-1RAs versus insulin. Conclusions: Using GLP-1RAs versus insulin for type 2 diabetes patients requiring intensified injection therapy in clinical practice is cost-effective.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12933-020-01211-4

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Summary of existing studies on cost-effectiveness of glucagon-like peptide-1 receptor agonists (GLP-1RAs) versus insulin therapy. GLP-1RAs: glucagon-like peptide-1 receptor agonists; TW: Taiwan; GDP: gross domestic product; USD: United States dollars; ICER: incremental cost-effectiveness ratio; QALY: quality-adjusted life year. (1) In 2019, the one-time per capita Taiwan’s GDP was US$25,893 and the three-time per capita Taiwan’s GDP was US$77,679. (2) This figure includes the articles summarized in Additional file 1: Table S5 expect for two published studies (Edwards et al. 2006 and Woehl et al. 2008) and our study. This is because the cost per QALY was not reported in Edwards et al.’s study (2006) and our study, and the use of exenatide was dominated by insulin glargine in Woehl et al.’s study (2008)
Fig. 1 Summary of existing studies on cost-effectiveness of glucagon-like peptide-1 receptor agonists (GLP-1RAs) versus insulin therapy. GLP-1RAs: glucagon-like peptide-1 receptor agonists; TW: Taiwan; GDP: gross domestic product; USD: United States dollars; ICER: incremental cost-effectiveness ratio; QALY: quality-adjusted life year. (1) In 2019, the one-time per capita Taiwan’s GDP was US$25,893 and the three-time per capita Taiwan’s GDP was US$77,679. (2) This figure includes the articles summarized in Additional file 1: Table S5 expect for two published studies (Edwards et al. 2006 and Woehl et al. 2008) and our study. This is because the cost per QALY was not reported in Edwards et al.’s study (2006) and our study, and the use of exenatide was dominated by insulin glargine in Woehl et al.’s study (2008)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 52 references

Cited by

See all 51

Metadata

Authors
Yang, C.-Y., Chen, Y.-R., Ou, H.-T., & Kuo, S.
Affiliations
  • National Cheng Kung University (TW)
  • National Cheng Kung University Hospital (TW)
  • University of Michigan (US)
Corresponding author
Ou, Huang-Tz
Venue
Cardiovascular Diabetology
Published
2021-01-19
Volume
20
Issue
1
Pages
21-21
ISSN
1475-2840 (ISSN-L)
OpenAlex
W3124422045
Cited by
51
References
52
Citations by year
2026: 12 · 2025: 11 · 2024: 12 · 2023: 8 · 2022: 6 · 2021: 2
FWCI
1.07
Type
journal article
Language
en
Open access
Licence
Locations
  • Cardiovascular Diabetology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Deep Blue (University of Michigan) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Ministry of Science and Technology, Taiwan (MOST 109-2320-B-006-047)
  • National Institute of Diabetes and Digestive and Kidney Diseases (P30DK092926)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
GLP-1 receptor agonists, insulin, type 2 diabetes, cost-effectiveness, intensive insulin therapy, all-cause mortality, number needed to treat, health care costs, real-world effectiveness
MeSH terms
Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Cost-Benefit Analysis, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Insulin, Drug Costs, Treatment Outcome, Models, Economic, Incretins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cost-effectiveness of GLP-1 receptor agonists versus insulin for the treatment of type 2 diabetes: a real-world study and systematic review. https://app.cochat.ai/papers/10.1186/s12933-020-01211-4
The paper
Yang, C.-Y., Chen, Y.-R., Ou, H.-T., & Kuo, S. (2021). Cost-effectiveness of GLP-1 receptor agonists versus insulin for the treatment of type 2 diabetes: a real-world study and systematic review. Cardiovascular Diabetology. https://doi.org/10.1186/s12933-020-01211-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.